Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody

被引:38
作者
Flick, MB
Sapi, E
Perrotta, PL
Maher, MG
Halaban, R
Carter, D
Kacinski, BM
机构
[1] YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA
[2] YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06520 USA
[3] YALE UNIV, SCH MED, DEPT OBSTET & GYNECOL, NEW HAVEN, CT 06520 USA
关键词
c-fms proto-oncogene; phosphotyrosine; immunohistochemistry; tyrosine kinase; breast carcinoma;
D O I
10.1038/sj.onc.1201092
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The macrophage colony stimulating factor receptor (CSF-1R), the product of the c-fms proto-oncogene, plays an important role in regulating the normal proliferation and differentiation of macrophages and trophoblasts. However, the abnormal expression of CSF-1R transcripts and protein by human breast carcinomas has been shown to correlate with advanced stage and poor prognosis. Ligand activated CSF-1R dimers transphosphorylate several tyrosines in their cytoplasmic domains which provide recognition sites for various effector proteins in multiple signal transduction pathways. In cells transformed by the c-fms oncogene, one of the major CSF-1R phosphotyrosines, pTyr723 is important for phenotypic expression of anchorage-independent growth and metastasis. In order to investigate the relationship between receptor activation/phosphorylation and cellular phenotypes in vitro and in vivo, we prepared a CSF-1R phosphorylation-state specific antibody raised against a specific phosphopeptide of CSF-1R, which included phosphorylated tyrosine 723. On immunoblots of lysates from cells expressing CSF-1R, this antibody recognizes phosphorylated CSF-1R in CSF-1 stimulated cells but not in unstimulated cells. As an immunohistochemical reagent, this antibody stained 52% of invasive human breast tumors (72% of CSF-1R positive cases) in a sample of 114 cases and 38% of carcinoma in situ. This data represents the first direct evidence of in vivo phosphorylation of CSF-1R in human breast carcinomas.
引用
收藏
页码:2553 / 2561
页数:9
相关论文
共 67 条
[1]   EGF or PDGF receptors activate atypical PKC lambda through phosphatidylinositol 3-kinase [J].
Akimoto, K ;
Takahashi, R ;
Moriya, S ;
Nishioka, N ;
Takayanagi, J ;
Kimura, K ;
Fukui, Y ;
Osada, S ;
Mizuno, K ;
Hirai, S ;
Kazlauskas, A ;
Ohno, S .
EMBO JOURNAL, 1996, 15 (04) :788-798
[2]   SEQUENCE REQUIREMENTS FOR BINDING OF SRC FAMILY TYROSINE KINASES TO ACTIVATED GROWTH-FACTOR RECEPTORS [J].
ALONSO, G ;
KOEGL, M ;
MAZURENKO, N ;
COURTNEIDGE, SA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (17) :9840-9848
[3]  
Bacus SS, 1996, AM J PATHOL, V148, P549
[4]  
BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO
[5]  
2-8
[6]   ANTISERUM RAISED AGAINST A SYNTHETIC PHOSPHOTYROSINE-CONTAINING PEPTIDE SELECTIVELY RECOGNIZES P185(NEU/ERBB-2) AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR [J].
BANGALORE, L ;
TANNER, AJ ;
LAUDANO, AP ;
STERN, DF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (23) :11637-11641
[7]   CHARACTERIZATION OF A NOVEL ANTI-PEPTIDE ANTIBODY THAT RECOGNIZES A SPECIFIC CONFORMATION OF THE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR [J].
BISHAYEE, S ;
MAJUMDAR, S ;
SCHER, CD ;
KHAN, S .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (09) :3696-3702
[8]  
BOHM M, 1995, CELL GROWTH DIFFER, V6, P291
[9]  
BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631
[10]  
BRUCKNER A, 1992, CANCER RES, V52, P3043